Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.38 USD
Change Today +0.345 / 5.72%
Volume 9.2K
HSGX On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

histogenics corp (HSGX) Snapshot

Open
$6.36
Previous Close
$6.03
Day High
$6.39
Day Low
$6.01
52 Week High
12/3/14 - $12.97
52 Week Low
07/29/15 - $5.87
Market Cap
84.3M
Average Volume 10 Days
11.8K
EPS TTM
--
Shares Outstanding
13.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HISTOGENICS CORP (HSGX)

Related News

No related news articles were found.

histogenics corp (HSGX) Related Businessweek News

No Related Businessweek News Found

histogenics corp (HSGX) Details

Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace. Its product candidate includes NeoCart, which is in Phase III clinical trials, a first-line therapy for full thickness knee chondral lesions in skeletally mature adults age 18 to 55. The company has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.

42 Employees
Last Reported Date: 03/27/15
Founded in 2000

histogenics corp (HSGX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $224.3K
Senior Vice President of Technical Operations
Total Annual Compensation: $309.2K
Compensation as of Fiscal Year 2014.

histogenics corp (HSGX) Key Developments

Histogenics Corporation Appoints Dr. Gloria Matthews as Chief Medical Officer

Histogenics Corporation announced the appointment of Dr. Gloria Matthews, DVM, Ph.D., DAVCS, as its Chief Medical Officer. Dr. Matthews brings more than 20 years of global research, development and surgical experience in orthopedics and cartilage repair to Histogenics, and in her new role, will oversee all clinical and medical affairs activities at Histogenics. She is an accomplished scientist, educator, guest speaker and surgeon with broad ranging expertise in orthopedic and rheumatologic diseases, among other therapeutic areas, and has significant functional experience in cellular and gene therapy, biomaterials and growth factors.

Histogenics Corporation Appoints Jonathan Lieber as Chief Financial Officer, Effective July 2, 2015

Histogenics Corporation announced the appointment of Jonathan Lieber as its Chief Financial Officer, effective July 2, 2015. Mr. Lieber has more than 20 years of executive management experience at emerging growth life sciences companies and in investment banking. He brings a track record of success, leading both development-stage and commercial companies throughout his career, and will oversee all financial, business development, investor relations and administrative functions at the company. Prior to the company, Mr. Lieber most recently served as the CFO of Metamark Genetics Inc., as the CFO and Treasurer of Repligen Corporation, and the CFO of Xcellerex Inc. (acquired by GE Healthcare).

Histogenics Corporation Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Histogenics Corporation announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, loss from operations was $7,873,000 compared to $5,173,000 a year ago. Loss attributable to common stockholders - basic and diluted was $7,964,000 or $0.60 basic and diluted per share compared to $3,437,000 or $5.90 basic and diluted per share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HSGX:US $6.38 USD +0.345

HSGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HSGX.
View Industry Companies
 

Industry Analysis

HSGX

Industry Average

Valuation HSGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HISTOGENICS CORP, please visit www.histogenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.